Navigation Links
Conversion in Medical Technology
... Ltd. in Houston, TX. "In this study, the conversion of VYVANSE to its active form was not affected ... form by the body's natural metabolism. This conversion takes place minimally in the gastrointestinal ... studies have demonstrated that the conversion of VYVANSE to active medication is unlikely to be ...
... of Cladribine Tablets in Preventing conversion to Definite Multiple Sclerosis in Addition to the ... and safety of Cladribine tablets in preventing conversion to definite multiple sclerosis." "As a leader ... endpoint of the ORACLE MS trial is time to conversion to MS, according to the McDonald criteria. Other ...
... In the study, known as the Atrial arrhythmia conversion Trial (ACT I), the primary efficacy analysis ... who received KYNAPID demonstrated the highest conversion rate (62.1%) compared with 4.9% with placebo. The median time to conversion to sinus rhythm for the 75 patients receiving ...
... agent vernakalant hydrochloride increased conversion to normal heart rhythm (sinus rhythm, or SR) ... surgeries." Study Results The Atrial arrhythmia conversion Trial or ACT II was a randomized, double-bind, ... the percentage of patients with treatment-induced conversion of AF/atrial flutter to SR for at least ...
... pediatric patients as young as 2 years and 2) for conversion to monotherapy in adults with partial ... established 1) as initial monotherapy, 2) for conversion to monotherapy from AEDs other ... primidone, or valproate, 3) for simultaneous conversion to monotherapy from two or more concomitant AEDs. ...
... agent vernakalant hydrochloride increased conversion to normal heart rhythm (sinus rhythm, or SR) ... The study, referred to as the atrial arrhythmia conversion trial or ACT I, was a prospective, randomized, ... was the percentage of patients demonstrating conversion to SR for at least one minute within 90 minutes ...
... the therapeutic benefit of Rebif(R) (interferon beta-1a) on the time to conversion to multiple sclerosis (MS) in people with a first clinical event ... three times a week. The primary endpoint of the REFLEX trial is time to conversion to MS, according to the McDonald criteria. Further endpoints include time ...
... of BACE1 in combination with other biomarker candidates for predicting the conversion from MCI to Alzheimer's. The additional candidates were abnormal brain ... (a genetic risk factor for Alzheimer's) were the strongest predictors of conversion to Alzheimer's, after controlling for age and gender. The classification ...
... - Data Support Intravenous to Subcutaneous conversion - SAN DIEGO, April 16 /PRNewswire-FirstCall/ -- Halozyme ... absorb bisphosphonates, it could prevent local irritation and facilitate conversion from intravenous infusion to a more convenient subcutaneous route of ...
... thoracic and cervical patients approximately four times greater than the conversion rate for patients in a comparable historical study who did not receive ... with cervical injuries, the interim efficacy data also suggest that the conversion rate was dose-dependent. The Congressional briefing, sponsored by ...
... delivered to mice (abstract no. 2131). A third poster describes the conversion of the commercial antibodies trastuzumab and cetuximab (Genentech's and ... Abstract No. 2131 (board #6, April 14, 2008) Lutterbuese, R. et al. conversion of Cetuximab and Trastuzumab into T Cell-engaging BiTE Antibodies Creates ...
... in which d-amphetamine is covalently bonded to l-lysine, and after oral ingestion it is converted to pharmacologically active d-amphetamine. The conversion of VYVANSE to d-amphetamine is not affected by gastrointestinal pH and is unlikely to be affected by alterations in GI transit times. Additional ...
... in which d-amphetamine is covalently bonded to l-lysine, and after oral ingestion it is converted to pharmacologically active d-amphetamine. The conversion of VYVANSE to d-amphetamine is not affected by gastrointestinal pH and is unlikely to be affected by alterations in normal GI transit times. ...
... outcomes. It demonstrated that initiating Betaseron treatment early in the disease reduced the risk of negative long-term outcomes, including conversion to secondary progressive multiple sclerosis (SPMS), reaching a confirmed EDSS of 6.0 or the use of a wheelchair. The study also found that the longer ...
... managed service provider any network or service can rapidly and cost-effectively implement SpinVox. At the heart of SpinVox is its Voice Message conversion System(TM) (VMCS), which works by combining state-of-the-art speech technologies with a live-learning language process. VMCS is being rolled-out ...
... demonstrated an improvement in their impairment level on the American Spinal Injury Association scale that was approximately 400% greater than the conversion rate for patients in a comparable historical study who did not receive Cethrin. When analyzed as a subset, patients with cervical (neck) injuries who ...
... which has shown clinical responses in relapsed and refractory non-Hodgkin's lymphoma patients." Reference (1) Lutterbuese, R. et al. conversion of Cetuximab and Trastuzumab into T Cell-engaging BiTE Antibodies Creates Novel Drug Candidates with Superior Anti-tumor Activity. Annual ...
... pain and headaches, says Dr. Marcus, who has found muscle involvement in over 75 percent of his chronic back pain patients. Dr. Marcus credits his conversion from helping patients live with their pain to actually curing them to Dr. Hans Kraus, the legendary physical medicine and rehabilitation specialist. ...
... dissociates very slowly, thereby preventing the degradation of GLP-1 at the site of action. Unbound ARI-2243 then undergoes a unique non-enzymatic conversion as it passes through the gut and into systemic circulation, which limits the exposure of the active species to unwanted targets, such as DPP 8 and 9. ...
... of Neurotrauma. When subjects with cervical injuries who were treated with Cethrin were analyzed separately, about 46% of the subjects exhibited a conversion rate from ASIA A to ASIA B or better. Moreover, about 18% of subjects overall and 38% of subjects with cervical injuries improved to ASIA C or better ...
... to fully address the questions raised by members of the Cardio-Renal Advisory Committee in its meeting to consider tedisamil as a treatment for rapid conversion of recent onset atrial fibrillation to normal sinus rhythm (NSR). The Committee voted against approval of tedisamil, at this time, requesting that ...
... MIRCERA(R), administered up to once every four weeks(1) The MAXIMA study is the first randomized, comparative study to investigate the direct conversion of dialysis patients with chronic kidney disease from treatment with erythropoiesis-stimulating agents (ESA) given one to three times a week to IV ...
... that Cethrin treated patients experience a frequency of post-treatment conversions from ASIA A to ASIA B or greater which is up to four times the conversion rate seen with the standard of care reported in the literature (6.7%, Burns et al., J. Neurotrauma, 2003). When subgroups of patients treated with ...
... AVODART, the first and only dual 5ARI for the treatment of enlarged prostate, inhibits both the type I and type II isoenzymes responsible for the conversion of testosterone into dihydrotestosterone (DHT). DHT is the primary male hormone responsible for the enlargement of the prostate. AVODART provides the ...
... one share of common stock. 13,842,590 of the Units were purchased for cash, with the balance of 9,962,961 Units issued in consideration for the conversion of all of the Company's $10.544 million in outstanding bridge loan indebtedness. Net cash proceeds to the Company, after expenses relating to closing ...
... million (approximately EUR 157 million or USD 204 million) from private placements of equity securities and two convertible loans including the conversion premiums. We have had total revenues, principally from milestone payments, of CHF 57.7 million (approximately EUR 37 million or USD 44 million). The ...
... of Cladribine Tablets in Preventing conversion to Definite Multiple Sclerosis in Addition to the ... and safety of Cladribine tablets in preventing conversion to definite multiple sclerosis." "As a leader ... endpoint of the ORACLE MS trial is time to conversion to MS, according to the McDonald criteria. Other ...
... In the study, known as the Atrial arrhythmia conversion Trial (ACT I), the primary efficacy analysis ... who received KYNAPID demonstrated the highest conversion rate (62.1%) compared with 4.9% with placebo. The median time to conversion to sinus rhythm for the 75 patients receiving ...
... agent vernakalant hydrochloride increased conversion to normal heart rhythm (sinus rhythm, or SR) ... surgeries." Study Results The Atrial arrhythmia conversion Trial or ACT II was a randomized, double-bind, ... the percentage of patients with treatment-induced conversion of AF/atrial flutter to SR for at least ...
... pediatric patients as young as 2 years and 2) for conversion to monotherapy in adults with partial ... established 1) as initial monotherapy, 2) for conversion to monotherapy from AEDs other ... primidone, or valproate, 3) for simultaneous conversion to monotherapy from two or more concomitant AEDs. ...
... agent vernakalant hydrochloride increased conversion to normal heart rhythm (sinus rhythm, or SR) ... The study, referred to as the atrial arrhythmia conversion trial or ACT I, was a prospective, randomized, ... was the percentage of patients demonstrating conversion to SR for at least one minute within 90 minutes ...
DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program
... to stable pain control and into the maintenance period (see above), the conversion ratios from oral morphine equivalents at baseline to TRANSDUR-Sufentanil ... Phase III program (including the dose titration regimens and dose conversion ratios expected to be utilized in the Phase III program) and regulatory ...... the therapeutic benefit of Rebif(R) (interferon beta-1a) on the time to conversion to multiple sclerosis (MS) in people with a first clinical event ... three times a week. The primary endpoint of the REFLEX trial is time to conversion to MS, according to the McDonald criteria. Further endpoints include time ...
... of BACE1 in combination with other biomarker candidates for predicting the conversion from MCI to Alzheimer's. The additional candidates were abnormal brain ... (a genetic risk factor for Alzheimer's) were the strongest predictors of conversion to Alzheimer's, after controlling for age and gender. The classification ...
Alliance Pharmaceutical Corp. Announces Approval of Proposed Actions at Annual Shareholders Meeting
... indebtedness have agreed to convert such debt into common stock at a conversion price of $0.17 per share. The material conditions to such conversion are: (i) that the company effect a reverse stock split in a ratio of ten ...... - Data Support Intravenous to Subcutaneous conversion - SAN DIEGO, April 16 /PRNewswire-FirstCall/ -- Halozyme ... absorb bisphosphonates, it could prevent local irritation and facilitate conversion from intravenous infusion to a more convenient subcutaneous route of ...
... thoracic and cervical patients approximately four times greater than the conversion rate for patients in a comparable historical study who did not receive ... with cervical injuries, the interim efficacy data also suggest that the conversion rate was dose-dependent. The Congressional briefing, sponsored by ...
... delivered to mice (abstract no. 2131). A third poster describes the conversion of the commercial antibodies trastuzumab and cetuximab (Genentech's and ... Abstract No. 2131 (board #6, April 14, 2008) Lutterbuese, R. et al. conversion of Cetuximab and Trastuzumab into T Cell-engaging BiTE Antibodies Creates ...
Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009
... No. APB 14-1 (FSP 14-1) for its 2 5/8% convertible notes, which required Isis to assign a value to its convertible debt without considering the conversion feature. As a result, Isis is recording its convertible debt at a discount, which Isis is amortizing over the expected life of the debt as ...Cognition Therapeutics Closes Series A Financing to Advance Drug Candidates for Alzheimer's Disease
... Pittsburgh Life Sciences Greenhouse, Innovation Works (Pittsburgh), and several individual investors. The round included both new investments and the conversion of existing convertible notes. "This investment facilitates the advancement of our existing lead molecules towards a major milestone," said ...Gen-Probe and DiagnoCure Amend Collaboration Agreement Surrounding PCA3-Based Prostate Cancer Tests
... and may be exchanged for common shares on a one-for-one basis. DiagnoCure has the option to redeem the preferred shares or to require their conversion into common shares in certain circumstances. As part of its investment in DiagnoCure, Gen-Probe will receive a liquidation preference in certain ...... in which d-amphetamine is covalently bonded to l-lysine, and after oral ingestion it is converted to pharmacologically active d-amphetamine. The conversion of VYVANSE to d-amphetamine is not affected by gastrointestinal pH and is unlikely to be affected by alterations in GI transit times. Additional ...
... in which d-amphetamine is covalently bonded to l-lysine, and after oral ingestion it is converted to pharmacologically active d-amphetamine. The conversion of VYVANSE to d-amphetamine is not affected by gastrointestinal pH and is unlikely to be affected by alterations in normal GI transit times. ...
... outcomes. It demonstrated that initiating Betaseron treatment early in the disease reduced the risk of negative long-term outcomes, including conversion to secondary progressive multiple sclerosis (SPMS), reaching a confirmed EDSS of 6.0 or the use of a wheelchair. The study also found that the longer ...
... managed service provider any network or service can rapidly and cost-effectively implement SpinVox. At the heart of SpinVox is its Voice Message conversion System(TM) (VMCS), which works by combining state-of-the-art speech technologies with a live-learning language process. VMCS is being rolled-out ...
Research Explains How Advanced Prostate Cancer Becomes Resistant to Androgen-Deprivation Therapy
... may have escaped the prostate. Mostaghel and colleagues feel the most promising drug targets will be inhibitors of CYP17 enzymes, which disrupt the conversion of progesterone to testosterone precursors, as well as inhibitors of enzymes that perform subsequent steps in testosterone production: AKR1C3 and ...... demonstrated an improvement in their impairment level on the American Spinal Injury Association scale that was approximately 400% greater than the conversion rate for patients in a comparable historical study who did not receive Cethrin. When analyzed as a subset, patients with cervical (neck) injuries who ...
... which has shown clinical responses in relapsed and refractory non-Hodgkin's lymphoma patients." Reference (1) Lutterbuese, R. et al. conversion of Cetuximab and Trastuzumab into T Cell-engaging BiTE Antibodies Creates Novel Drug Candidates with Superior Anti-tumor Activity. Annual ...
... pain and headaches, says Dr. Marcus, who has found muscle involvement in over 75 percent of his chronic back pain patients. Dr. Marcus credits his conversion from helping patients live with their pain to actually curing them to Dr. Hans Kraus, the legendary physical medicine and rehabilitation specialist. ...
Novavax Reports Fourth Quarter and 2007 Year-End Financial Results
... cash and short term investment balances in 2007. The relatively small change for the full year of $0.1 million in 2007 versus 2006 was due to the conversion of $7.0 million of long term debt into equity in 2006, thereby lowering interest expense, partially offset by lower interest income due to lower cash ...... dissociates very slowly, thereby preventing the degradation of GLP-1 at the site of action. Unbound ARI-2243 then undergoes a unique non-enzymatic conversion as it passes through the gut and into systemic circulation, which limits the exposure of the active species to unwanted targets, such as DPP 8 and 9. ...
... of Neurotrauma. When subjects with cervical injuries who were treated with Cethrin were analyzed separately, about 46% of the subjects exhibited a conversion rate from ASIA A to ASIA B or better. Moreover, about 18% of subjects overall and 38% of subjects with cervical injuries improved to ASIA C or better ...
... to fully address the questions raised by members of the Cardio-Renal Advisory Committee in its meeting to consider tedisamil as a treatment for rapid conversion of recent onset atrial fibrillation to normal sinus rhythm (NSR). The Committee voted against approval of tedisamil, at this time, requesting that ...
Clinical Data Presented on OrthoGlide(R) Medial Knee Implant
... either a unicompartmental knee or TKR. Nine OrthoGlide patients enrolled (10.2%) were converted, which is comparable to the 9% unicompartmental knee conversion rate at two years post-operative. Also important is the fact that only one patient out of 350 total implants (includes study and non-study patients) ...Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
... - 11,890 - Operating income (loss) 3,453 (8,691) (13,191) (18,727) Other income and (expense): Beneficial conversion of convertible security - - - (12,215) Investment and other income 188 466 ...... MIRCERA(R), administered up to once every four weeks(1) The MAXIMA study is the first randomized, comparative study to investigate the direct conversion of dialysis patients with chronic kidney disease from treatment with erythropoiesis-stimulating agents (ESA) given one to three times a week to IV ...
... that Cethrin treated patients experience a frequency of post-treatment conversions from ASIA A to ASIA B or greater which is up to four times the conversion rate seen with the standard of care reported in the literature (6.7%, Burns et al., J. Neurotrauma, 2003). When subgroups of patients treated with ...
... AVODART, the first and only dual 5ARI for the treatment of enlarged prostate, inhibits both the type I and type II isoenzymes responsible for the conversion of testosterone into dihydrotestosterone (DHT). DHT is the primary male hormone responsible for the enlargement of the prostate. AVODART provides the ...
... one share of common stock. 13,842,590 of the Units were purchased for cash, with the balance of 9,962,961 Units issued in consideration for the conversion of all of the Company's $10.544 million in outstanding bridge loan indebtedness. Net cash proceeds to the Company, after expenses relating to closing ...
Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
... 8,642 19,851 16,951 Operating loss (9,542) (3,422) (16,644) (10,035) Other (expense) and income: Beneficial conversion of convertible security - - - (12,215) Investment and other income 482 294 797 ...New Data Shows Once a Day Lamictal XR is Effective in Treating Patients with Partial Seizures
... of age and older with epilepsy. The open label, conversion study consisted of a 2 week base line phase ... patients as young as 2 years and 2) for conversion to monotherapy in adults with partial seizures ... established 1) as initial monotherapy, 2) for conversion to monotherapy from AEDs other than ...Cardiome And Astellas Announce Positive Results From ACT 2 Trial
... patients dosed with vernakalant (iv) experienced conversion to normal heart rhythm within 90 minutes, as ... of dosing. "We are delighted to see a 47% conversion rate in post-operative atrial fibrillation ... drug being evaluated for the acute conversion of atrial fibrillation (AF). Positive top-line ...... million (approximately EUR 157 million or USD 204 million) from private placements of equity securities and two convertible loans including the conversion premiums. We have had total revenues, principally from milestone payments, of CHF 57.7 million (approximately EUR 37 million or USD 44 million). The ...
Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
... million (approximately EUR 157 million or USD 204 million) from private placements of equity securities and two convertible loans including the conversion premiums. We have had total revenues, principally from milestone payments, of CHF 57.7 million (approximately EUR 37 million or USD 44 million). The ...Other ContentsOther TagsOther Tags
(Date:6/19/2013)... the most potent physiological anabolic agent for tissue-building ... of lipids, protein and carbohydrates, and inhibiting their ... also plays a major role in stimulating glucose ... metabolized and removed from the blood following meals. ... mechanisms by which insulin regulates glucose uptake in ...
(Date:6/19/2013)... University study offers further proof that the divergence of ... years ago was profoundly influenced by mutations to DNA ... off. , The study, published June 9 in ... that regulation of genes must play an important role ... and chimps in the proteins produced by genes. Indeed, ...
(Date:6/18/2013)... Paris Air Show – Marvin Test ... a leading provider of innovative test solutions for ... solutions this week at the Paris Air ... including increasingly complex armament systems with longer lifecycles, ... test solutions that address legacy system obsolescence. Marvin ...
Breaking Biology News(10 mins):Breakthrough research of essential molecule reveals important targets in diabetes and obesity 2New research backs theory that genetic 'switches' play big role in human evolution 2New research backs theory that genetic 'switches' play big role in human evolution 3Marvin Test Solutions Demonstrates Next-Generation Armament Test Solutions at Paris Air Show 2Marvin Test Solutions Demonstrates Next-Generation Armament Test Solutions at Paris Air Show 3(Date:6/19/2013)... 19, 2013 Amerinet, Inc, a ... Healthcare Technologies to help Pacific Medical Centers implement ... of more than 17 percent over the organization’s ... , “Driving economies of scale and process standardization ... challenges facing multi-site providers,” said Shawn Padilla, director ...
(Date:6/19/2013)... Elsevier, a world-leading provider of scientific, technical ... the publication of the National Osteoporosis Guideline Group ... osteoporosis in postmenopausal women and older men in ... 2009 in Maturitas , the original guidelines ... timely with an additional focus on the management ...
(Date:6/19/2013)... June 19, 2013 Imprivata ®, ... today announced that Imprivata OneSign ® leads the ... Mid-Term Performance Review: Software & Services report . CIOs ... Imprivata on the superior performance of its products and ... they indicate that Imprivata is integral to their long-term ...
(Date:6/19/2013)... 2013 According to Transparency Market Research ... Trends, Analysis and Forecast, 2011 – 2017,” the global ... the year 2011 and is expected to reach USD ... 9.7% from 2011 to 2017. Flexible endoscopes formed the ... USD 2,201 million for the year 2011. , Related ...
(Date:6/19/2013)... Despite the fact that the incidence of cancer is ... age, we still have an inadequate understanding on how ... though elderly patients are occasionally included in clinical trials, ... ,healthy, (fit) elderly patients. Thus, the broader elderly patient ... EORTC Cancer in the Elderly Task Force is now ...
Breaking Medicine News(10 mins):Health News:Amerinet Partners with ARAMARK Healthcare Technologies to Help Pacific Medical Centers Save 17 Percent and Better Manage System-Wide Equipment Program 2Health News:Imprivata Tops Single Sign-On Category in KLAS 2013 Mid-Term Performance Review 2Health News:Imprivata Tops Single Sign-On Category in KLAS 2013 Mid-Term Performance Review 3Health News:Endoscopy Devices Market Will Reach USD 10.8 Billion in 2017 : Transparency Market Research 2Health News:Endoscopy Devices Market Will Reach USD 10.8 Billion in 2017 : Transparency Market Research 3Health News:EORTC study opens for elderly patients with HER-2 positive metastatic breast cancer 2[0] Amerinet Partners with ARAMARK Healthcare Technologies to Help Pacific Medical Centers Save 17 Percent and Better Manage System-Wide Equipment Program[0] Maturitas publishes 2013 update on diagnosis and management of osteoporosis[0] Imprivata Tops Single Sign-On Category in KLAS 2013 Mid-Term Performance Review[0] Endoscopy Devices Market Will Reach USD 10.8 Billion in 2017 : Transparency Market Research[0] EORTC study opens for elderly patients with HER-2 positive metastatic breast cancer
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |